Xenon Pharmaceuticals (NASDAQ:XENE) Downgraded to "Strong Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Xenon Pharmaceuticals to “strong sell” from “sell,” although the broader analyst consensus remains “Moderate Buy” with an average price target of $70.93.
• XENE opened at $39.75, well below its 50-day and 200-day moving averages, while analysts recently cut price targets to $46–$90. The company reported a quarterly EPS loss of $1.11, slightly better than expectations, but analysts forecast a full-year loss of $4.73 per share.
• Clinical and regulatory risks have increased: Xenon submitted azetukalner for FDA review in focal seizures but paused new enrollment in depression and bipolar-disorder trials after adverse events, creating uncertainty around the drug’s broader psychiatric potential.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

XENE has been the subject of a number of other reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $46.00 price objective (down from $90.00) on shares of Xenon Pharmaceuticals in a research report on Friday. Wells Fargo & Company reduced their price objective on Xenon Pharmaceuticals from $69.00 to $64.00 and set an "overweight" rating on the stock in a research note on Friday. Robert W. Baird decreased their target price on Xenon Pharmaceuticals from $97.00 to $90.00 and set an "outperform" rating for the company in a research report on Friday. Finally, Wedbush lowered their target price on Xenon Pharmaceuticals from $71.00 to $55.00 and set an "outperform" rating for the company in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $70.93.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $39.75 on Friday. The firm has a market capitalization of $3.84 billion, a price-to-earnings ratio of -8.39 and a beta of 0.61. Xenon Pharmaceuticals has a one year low of $35.97 and a one year high of $72.66. The company's 50 day moving average price is $62.12 and its 200 day moving average price is $57.94.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same quarter in the previous year, the company earned ($1.07) EPS. Sell-side analysts forecast that Xenon Pharmaceuticals will post -4.73 EPS for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 10,000 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total value of $640,600.00. Following the completion of the transaction, the director directly owned 1,870 shares of the company's stock, valued at $119,792.20. This represents a 84.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Christopher Kenney sold 7,068 shares of the firm's stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $60.25, for a total value of $425,847.00. Following the sale, the insider owned 2 shares of the company's stock, valued at $120.50. This represents a 99.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.91% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Tidal Investments LLC grew its stake in Xenon Pharmaceuticals by 33.1% during the 2nd quarter. Tidal Investments LLC now owns 8,283 shares of the biopharmaceutical company's stock valued at $500,000 after purchasing an additional 2,058 shares in the last quarter. Engineers Gate Manager LP raised its position in shares of Xenon Pharmaceuticals by 566.8% in the 2nd quarter. Engineers Gate Manager LP now owns 62,183 shares of the biopharmaceutical company's stock valued at $3,753,000 after purchasing an additional 52,857 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at approximately $6,813,000. Arizona State Retirement System raised its position in shares of Xenon Pharmaceuticals by 2.3% in the 2nd quarter. Arizona State Retirement System now owns 22,382 shares of the biopharmaceutical company's stock valued at $1,351,000 after purchasing an additional 513 shares in the last quarter. Finally, Nykredit A S purchased a new position in shares of Xenon Pharmaceuticals during the 2nd quarter valued at approximately $67,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Xenon submitted an NDA for azetukalner in focal seizures, advancing the drug toward potential commercialization in an indication that analysts believe still supports the program’s core value. Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures
• Positive Sentiment: Despite lowering their estimates, RBC Capital Markets, Wedbush, Robert W. Baird and Needham retained positive ratings, indicating analysts continue to see meaningful value in the focal-seizure opportunity. Xenon Pharmaceuticals’ Azetukalner Retains Core Epilepsy Value
• Neutral Sentiment: Analysts cut price targets to ranges of $55 to $90, but maintained “outperform” or “buy” recommendations. The revisions reflect greater risk from the psychiatry program rather than a loss of confidence in the company’s epilepsy prospects.
• Negative Sentiment: Xenon voluntarily paused new enrollment in major depression and bipolar depression studies after reports of mental- and nervous-system-related adverse events. The company said the events were consistent with azetukalner’s known safety profile, but they had not been observed in the earlier Phase 2 X-NOVA depression trial, raising uncertainty about the drug’s broader psychiatric potential. Xenon Pauses Depression and Bipolar Trial Enrollment
• Negative Sentiment: The enrollment pause increases regulatory, timeline and commercial risks for a key expansion opportunity and triggered unusually heavy trading as investors reassessed azetukalner’s risk-benefit profile. Xenon Pharmaceuticals Falls After Depression Trial Enrollment Pause

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc NASDAQ: XENE is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its expertise in ion channels, which regulate the electrical activity of nerve cells, to discover and advance potential treatments for conditions with significant unmet medical needs.

Xenon's leading investigational product is azetukalner (XEN1101), an oral, small-molecule potassium-channel opener being studied in epilepsy, including focal-onset seizures, and major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.